Michael Wyatt to Cell Cycle Proteins
This is a "connection" page, showing publications Michael Wyatt has written about Cell Cycle Proteins.
Connection Strength
1.979
-
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
Score: 0.671
-
Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther. 2012 Aug; 11(8):1683-92.
Score: 0.361
-
PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25.
Score: 0.332
-
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer. Expert Opin Drug Discov. 2023 01; 18(1):65-81.
Score: 0.186
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
Score: 0.171
-
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066.
Score: 0.155
-
Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014 Jul; 9(7):773-89.
Score: 0.102